These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 34975912)

  • 1. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
    Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
    Front Immunol; 2021; 12():799206. PubMed ID: 34975912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T-cell therapy for solid tumours.
    The Lancet Oncology
    Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740
    [No Abstract]   [Full Text] [Related]  

  • 5. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
    Yang P; Meng M; Zhou Q
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
    Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T-cells profiling in carcinogenesis and tumorigenesis: An overview of CAR T-cells cancer therapy.
    Samadani AA; Keymoradzdeh A; Shams S; Soleymanpour A; Rashidy-Pour A; Hashemian H; Vahidi S; Norollahi SE
    Int Immunopharmacol; 2021 Jan; 90():107201. PubMed ID: 33249047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of resistance and escape to CAR-T cells].
    Grinda T; Brouard J; Tran D; Rubio MT
    Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.
    Zhu L; Yang X; Zhong D; Xie S; Shi W; Li Y; Hou X; HuaYao ; Zhou H; Zhao M; Ding Z; Zhao X; Mo F; Yin S; Liu A; Lu X
    J Immunol Res; 2020; 2020():2454907. PubMed ID: 32964055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
    Han X; Wang Y; Wei J; Han W
    J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-Ts: new perspectives in cancer therapy.
    Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
    FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.